57 related articles for article (PubMed ID: 18555840)
1. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility.
Weng W; Breslow JL
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14788-94. PubMed ID: 8962133
[TBL] [Abstract][Full Text] [Related]
2. A Proof-of-Concept for a Hypolipidemic Brown Trout Model.
Lourenço T; Rocha E; Gonçalves JF; Rocha MJ; Madureira TV
Toxics; 2024 Mar; 12(3):. PubMed ID: 38535952
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Qin S; Liu T; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
[TBL] [Abstract][Full Text] [Related]
4. Effect of rosuvastatin treatment on cholesterol efflux from human macrophages.
Kralova Lesna I; Adamkova V; Pagacova L
Neuro Endocrinol Lett; 2011; 32 Suppl 2():24-8. PubMed ID: 22101878
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL.
Marchesi M; Parolini C; Caligari S; Gilio D; Manzini S; Busnelli M; Cinquanta P; Camera M; Brambilla M; Sirtori CR; Chiesa G
Br J Pharmacol; 2011 Nov; 164(5):1460-8. PubMed ID: 21486287
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Shimizu T; Miura S; Tanigawa H; Kuwano T; Zhang B; Uehara Y; Saku K
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2246-53. PubMed ID: 25104799
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
9. [Receptors and molecular heterogeneity of lipoprotein particles containing apolipoprotein A-I].
Broutin H; Puchois P; Ailhaud G; Barbaras R; Torpier G; Fruchart JC
Ann Biol Clin (Paris); 1988; 46(1):16-23. PubMed ID: 2839056
[TBL] [Abstract][Full Text] [Related]
10. [Rosuvastatin: pharmacologic features].
Bernini F; Catapano AL
Ital Heart J; 2003 Dec; 4 Suppl 7():22S-32S. PubMed ID: 14983744
[TBL] [Abstract][Full Text] [Related]
11. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.
Hanefeld M
Int J Clin Pract; 2001; 55(6):399-405. PubMed ID: 11501230
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
